Abstract: Provided is a nonhuman animal model that is obtained by modifying a gene encoding thioredoxin and useful as a disease model of aging, kidney diseases, cardiovascular diseases, hypertension, aortic dissection, chronic obstructive lung disease, age-dependent epilepsy, abnormality of lipid metabolism, anemia, osteoporosis, abnormal immunity, etc. These variety of phenotypes are caused by the fact that a modification of a gene encoding thioredoxin induces hypofunction of thioredoxin expressed in multiple organs throughout the body. The gene encoding thioredoxin is a gene selected from among TXN, TRX, TRX1, RRDX, Txn1, Txn, Trx1 and ADF.

Abstract: Provided is an inhalation gas device for a therapy of a disease accompanied by epileptiform discharges comprising a medical gas bottle, and a medical inhalation gas device connected to the medical gas bottle, the inhalation gas device for a therapy of a disease accompanied by epileptiform discharges including the following 1) and 2): 1) a therapeutic agent for a disease accompanied by epileptiform discharges containing carbon dioxide as an active ingredient being filled in the medical gas bottle; and 2) the medical inhalation gas device being provided with a gas inhalation mask.

Abstract: Provided is a therapeutic agent for a disease accompanied by epileptiform discharges, which is easily-handled, has a low side effect, and has a fast acting property. By controlling the concentration of carbon dioxide of inhaled air, it is possible to change the pH in body fluids to an acidic side to reduce epileptiform discharges. Carbon dioxide is an active ingredient of a therapeutic agent for a disease accompanied by epileptiform discharges.

Abstract: Provided is a detection kit for detecting target genes of miRNA. Also provided is a method of detecting target genes of miRNA in a simple manner without the need for performing a transfection operation of a gene into cells via a vector. The detection kit is a detection kit for target genes of microRNA, including a cell extraction reagent, and a labeling reagent for microRNA or labeled microRNA, and further including a reaction reagent for the labeling substance for microRNA. mRNA corresponding to target genes of miRNA can be easily pulled down by producing a cell extract under mild conditions, adding labeled miRNA to the cell extract, and recovering the labeling substance. cDNA is produced from the pulled down mRNA to detect target genes of miRNA.

Abstract: Provided is a method of assessing a potential for development of Dravet syndrome with high accuracy, and use thereof. The method according to the present invention of assessing a potential for development of Dravet syndrome includes, with use of a sample taken from a subject, detecting whether or not a mutation is on ?-subunit type 1 of voltage-gated sodium ion channel NaV1.1, and detecting whether or not a mutation is on ?-subunit type 1 of voltage-gated calcium ion channel CaV2.1.

Abstract: Provided is a method of assessing a potential for development of Dravet syndrome with high accuracy, and use thereof. The method according to the present invention of assessing a potential for development of Dravet syndrome includes, with use of a sample taken from a subject, detecting whether or not a mutation is on ?-subunit type 1 of voltage-gated sodium ion channel NaV1.1, and detecting whether or not a mutation is on ?-subunit type 1 of voltage-gated calcium ion channel CaV2.1.

Abstract: Provided is a detection kit for detecting target genes of miRNA. Also provided is a method of detecting target genes of miRNA in a simple manner without the need for performing a transfection operation of a gene into cells via a vector. The detection kit is a detection kit for target genes of microRNA, including a cell extraction reagent, and a labeling reagent for microRNA or labeled microRNA, and further including a reaction reagent for the labeling substance for microRNA. mRNA corresponding to target genes of miRNA can be easily pulled down by producing a cell extract under mild conditions, adding labeled miRNA to the cell extract, and recovering the labeling substance. cDNA is produced from the pulled down mRNA to detect target genes of miRNA.

Abstract: Provided is a method of assessing a potential for development of Dravet syndrome with high accuracy, and use thereof. The method according to the present invention of assessing a potential for development of Dravet syndrome includes, with use of a sample taken from a subject, detecting whether or not a mutation is on ?-subunit type 1 of voltage-gated sodium ion channel NaV1.1, and detecting whether or not a mutation is on ?-subunit type 1 of voltage-gated calcium ion channel CaV2.1.

Abstract: An object of the present invention is to provide a test method for MALT lymphomas for providing genetic diagnosis data which can be used for the diagnosis of MALT lymphomas, identification of disease type, and prediction of progression of pathological conditions and onset thereof and a kit for implementing the method. At least two types of tumor-suppressor genes or cancer-related genes are selected, in particular, at least two types of genes are selected from a gene group consisting of 11 genes in a sample, and the expression levels or the gene expression regulation status of the selected genes are investigated. Early detection and diagnosis with high sensitivity and accuracy can be conducted by quantitatively determining the genetic product and preparing the expression profiles of the gene group on the basis of the results, or by detecting methylation frequencies to analyze the expression regulation.

Abstract: A therapeutic agent for soft tissue sarcoma (particularly synovial sarcoma) contains a histone deacetylase inhibitor (particularly compound of formula I) as an active ingredient

Abstract: A therapeutic agent for soft tissue sarcoma (particularly synovial sarcoma), contains a histone deacetylase inhibitor (particularly a compound of formula I) as an active ingredient

Abstract: The present invention relates to a therapeutic agent for soft tissue sarcoma (particularly synovial sarcoma), which contains a histone deacetylase inhibitor (particularly compound A) as an active ingredient.